Additionally, IL-17A is known for promoting the migration of human CD4+ T-cells across the blood-brain barrier (40), potentially explaining the reduced CD4+ response observed in the peripheral blood of MS patients in this study. This evidence concerns the gene IL17A and myeloid sarcoma.